Examination of Efficacy and safety of Bepotastine besilate (TALION Tablets) for pruritic skin diseases in scar

Examination of Efficacy and safety of Bepotastine besilate (TALION Tablets) for pruritic skin diseases in scar - Examination of Efficacy and safety of Bepotastine besilate (TALION Tablets) for pruritic skin diseases in scar

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005730

Enrollment

Registered

2011-06-07

Start date

2015-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pruritic skin diseases in scar

Interventions

Top the offered figure in the existing treatment group

and Bepotastine (eight weeks) Existing treatment group (eight weeks)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients who were pruritic skin diseases in scar 2) Patients who have pruritus which does not disappear by existing treatment cored VAS>=30 3)Patients who gave their written informed consent after explanation of the study

Exclusion criteria

Exclusion criteria: 1)Patients who are renal dysfunction 2)Patients who are pregnant or might be pregnant 3)Patients who are considered unsuitable for this study by the investigator

Design outcomes

Primary

Measure	Time frame
Subjective sign and objective symptom	—

Secondary

Measure	Time frame
1)Subjective symptoms: itch, spontaneous pain, pain on pressure,sense of tumoral and evaluate the degree of the feeling in VAS(100mm) 2)Objective symptom : Skin symptom (color, wrinkle, luster, height, flare around the scar, expansion of the scar) last total improvement , usefulness Discontinuation rate by ineffectiveness	—

Countries

Japan

Contacts

Public ContactJiro Katahira

Tokyo Woman's Medical University Plastic surgery

03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026